Rybelsus 3 mg Tablet (10 Tab)

Rybelsus 3 mg Tablet Overview:

Rybelsus 3 mg Tablet contains semaglutide, a GLP-1 receptor agonist that helps regulate appetite and blood sugar levels. It works by enhancing insulin secretion, reducing excess glucagon, and slowing gastric emptying, which promotes a feeling of fullness and lowers calorie intake.

It is prescribed as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity, or those who are overweight with weight-related conditions such as Type 2 Diabetes, hypertension, or dyslipidaemia. In addition, it is indicated to reduce the risk of major cardiovascular events, including heart attack, stroke, and cardiovascular death, in adults with established heart disease and excess weight.

Composition:

Each tablet contains Semaglutide 3 mg.

Excipients: Salcaprozate sodium, Cellulose microcrystalline, Povidone K 90, Magnesium stearate.

Uses and Benefits of Rybelsus 3 mg Tablet:

Rybelsus 3 mg Tablet is prescribed for the following conditions:

• Weight Management- Helps in weight loss for adults who are overweight or obese by increasing fullness, slowing stomach emptying, and reducing appetite.
• Cardiovascular Risk Reduction- Helps lower the risk of major cardiovascular events, including heart attack, stroke, or cardiovascular death, in adults with established heart disease who are overweight or obese.
• Weight Related Comorbid Condition- Used along with a reduced-calorie diet and increased physical activity in adults with obesity (BMI =30 kg/m²), or those who are overweight (BMI =27 kg/m²) with conditions such as hypertension, type 2 diabetes mellitus, or dyslipidaemia.
• Type 2 Diabetes Mellitus- Rybelsus 3 mg Tablet indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

How Rybelsus 3 mg Tablet works:

Rybelsus 3 mg Tablet contains semaglutide, a GLP-1 receptor agonist that replicates the action of the body’s natural incretin hormone involved in blood sugar and appetite regulation. It promotes insulin release when glucose levels are elevated and reduces glucagon secretion, thereby helping maintain balanced blood sugar levels. Additionally, it delays stomach emptying and influences appetite-regulating centers in the brain, leading to increased satiety, reduced hunger, and lower calorie intake.

Dosage of Rybelsus 3 mg Tablet:

• Usage Direction

Rybelsus 3 mg Tablet is intended for oral use only and should be taken strictly as per the endocrinologists, internal medicine specialists, and cardiologists. Rybelsus should be swallowed whole with water and do not crush, chew or break the tablet. Take Rybelsus 3 mg Tablet preferably at the same time each day. Do not stop or alter the dose of Rybelsus without consulting your endocrinologists, internal medicine specialists, and cardiologists, as this may prevent you from achieving the desired result. If you are unsure about the administration procedures of this medication, consult with your endocrinologists, internal medicine specialists, and cardiologists.

• Missed Dose

If you miss a dose of Rybelsus 3 mg Tablet, take it as soon as you remember on the same day. But, if it is almost time for your next scheduled dose, skip the one you missed and continue following your regular dosing schedule. Do not attempt to take two doses if you have forgotten one. If you often forget to take your medication, consult with your doctor to re-evaluate your dosing schedule. Frequently missing doses could lead to undesired outcomes.

You can set reminders on your smartphone, keep drug organizer boxes, or use other audio-visual technologies to prevent missing a dose.

• Overdose

In case of overdose, symptoms may include severe nausea, vomiting, and low blood sugar. Immediate medical attention is recommended. Appropriate supportive care and monitoring are necessary according to the clinical signs and symptoms of overdose for Rybelsus 3 mg Tablet.

Contraindications of Rybelsus 3 mg Tablet:

Do not take Rybelsus 3 mg Tablet if you are allergic or hypersensitive to Semaglutide or any of its components. Additionally, Rybelsus is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Rybelsus should be avoided in individuals with a personal or family history of medullary thyroid carcinoma (MTC). It is also not recommended for patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), a genetic disorder that increases the risk of thyroid cancer.

Rybelsus 3 mg Tablet is also contraindicated in patients with known hypersensitivity (allergic reaction) to Semaglutide or any of its excipient ingredients. Additionally, Rybelsus 3 mg Tablet should not be combined with other Semaglutide-containing products or with any other GLP-1 receptor agonist medicines.

Precautions & Warnings of Rybelsus 3 mg Tablet:

Before starting Rybelsus, inform your endocrinologists, internal medicine specialists, and cardiologists about your medical history, especially if you have or have had pancreatic or kidney problems, or Type 2 Diabetes with a history of diabetic retinopathy. Also mention if you are scheduled for surgery or procedures involving anesthesia or deep sedation. Endocrinologists, internal medicine specialists, and cardiologists should evaluate the risk-benefit profile before initiating therapy.

Side Effects of Rybelsus 3 mg Tablet:

Rybelsus 3 mg Tablet should be taken strictly under medical supervision, as it may cause significant adverse effects. The most common side effects include nausea, vomiting, diarrhea, constipation, and loss of appetite, which are usually mild and tend to improve as the body adjusts. However, if these symptoms continue, it is important to consult endocrinologists, internal medicine specialists, and cardiologists.

Other possible effects include dizziness, mild increased heart rate (tachycardia), headache, infections, and indigestion. Although severe & rare side effects may occur and require immediate medical attention. These include pancreatitis, acute kidney injury, worsening of diabetic retinopathy, gastroparesis (slowed or stopped stomach emptying), bowel obstruction, gallbladder-related complications such as gallstones, medullary thyroid cancer and bile duct blockage.

Use of Rybelsus 3 mg Tablet may lead to noticeable physical changes as a result of rapid weight loss. One such effect is loss of facial fat, which can make the face appear hollow or sunken. This may be associated with features such as sunken eyes, increased wrinkles, sagging around the jawline (jowls), and changes in the appearance of the lips, cheeks, or chin.

Potential Health Complications of Rybelsus 3 mg Tablet:

Potential health complications of Rybelsus 3 mg Tablet may occur in some individuals despite its effectiveness. These include serious allergic reactions (anaphylaxis), which can present as shortness of breath, red rash, hives, abdominal pain, difficulty swallowing, chest tightness, or a sudden feeling of anxiety or doom.

Additionally, low blood sugar (hypoglycemia) may occur, particularly in patients with Type 2 Diabetes, with symptoms such as shaking, sweating, chills, dizziness, weakness, rapid heartbeat, intense hunger, difficulty concentrating, pale skin, or nausea.

Immediate medical attention is essential if any of these symptoms develop, and the medicine should always be used under proper medical supervision to minimize risks.

Safety Related Concerns of Rybelsus 3 mg Tablet:

• Pregnancy

Rybelsus 3 mg Tablet is not recommended during pregnancy, as it may pose a risk of harm to the developing fetus, including potential abnormalities. Women who are pregnant or planning to conceive should avoid using this medication, and appropriate medical advice should be taken.

• Breastfeeding

Breastfeeding mothers are advised to avoid Rybelsus 3 mg Tablet as it may pass through breast milk and can cause side effects in breastfed babies.

• Alcohol

Alcohol may worsen gastrointestinal side effects like nausea and may affect blood sugar levels. Limiting alcohol intake is advisable.

• Driving & Using Machinery

Rybelsus generally does not affect the ability to drive. However, caution is advised if you experience dizziness or low blood sugar, especially when used with other diabetes medicines.

• Food Interactions

There are no strict food restrictions, but following a reduced-calorie, balanced diet is essential for effectiveness. Fatty meals may worsen nausea.

• Drug Interactions

Rybelsus may increase the risk of low blood sugar when used with insulin or insulin secretagogues (e.g., sulfonylureas), so dose adjustment may be needed. It also slows stomach emptying, which can affect how some oral medicines work. For example, levels of Levothyroxine may increase. Regular monitoring is advised when taking other medicines with Rybelsus 3 mg Tablet.

Always inform your endocrinologists, internal medicine specialists, and cardiologists and pharmacist about all medications you are taking, including prescription drugs, over-the-counter medications, vitamins, and herbal supplements, to avoid potential interactions.

Storage of Rybelsus 3 mg Tablet:

• Do not store above 30°C.
• Store in the original blister package to protect from moisture and light.
• Keep out of the sight and reach of children.
• Do not use Rybelsus 3 mg Tablet past its expiration date printed on the package. Dispose of expired or unused medications properly according to local guidelines or take them to a pharmacy take-back program.

Important Information:

• Read the package leaflet before use.
• Check your blood sugar levels regularly to see how the medication is working.
• Make sure to have quick sugar supplies on hand for low blood sugar episodes.
• Aim for at least 30 minutes of moderate activity daily, under supervision.
• Avoid unhealthy fatty foods or junk foods, such as deep fried snacks, packaged snacks, sugary items, and fast foods.
  

Related Blood Glucose Monitoring Systems:

To manage diabetes at home, discover our simple, reliable home-use Blood Glucose Monitoring systems with Test Strips. Check Out

Frequently Asked Questions:

Q. What is Rybelsus 3 mg Tablet used for?

A: Rybelsus 3 mg Tablet contains semaglutide, a GLP-1 receptor agonist that helps control appetite and blood sugar by increasing insulin, lowering glucagon, and slowing digestion. It is used with diet and exercise for weight management in obesity or overweight with conditions like Type 2 Diabetes, and reduces the risk of major cardiovascular events.

Q. How quickly does Rybelsus 3 mg Tablet work?

A: Results vary from person to person depending on metabolism, lifestyle, and dose. Some people may notice reduced appetite within the first few weeks, while meaningful weight loss typically develops gradually over a few months. Consistent use along with diet and exercise is important for best results.

Q. Can Rybelsus 3 mg Tablet reduce heart disease risk?

A: Yes, Rybelsus 3 mg Tablet has been shown to reduce the risk of major cardiovascular events such as heart attack, stroke, and cardiovascular death in adults with existing heart disease and excess weight. This benefit is linked to its effects on weight reduction, blood sugar control, and overall metabolic health.

Q. Can I take Rybelsus with other weight loss medicines?

A: It is generally not recommended to use Rybelsus 3 mg Tablet with other weight loss medications unless advised by your doctor. Combining such treatments may increase the risk of side effects or complications. Always consult an endocrinologists, internal medicine specialists, and cardiologists before using any additional medicines for weight loss.

Q. Do I need a prescription for Rybelsus 3 mg Tablet?

A: Yes, Rybelsus is a prescription-only medicine. It can only be prescribed by endocrinologists, internal medicine specialists, and cardiologists to ensure proper dosing, monitoring, and safety.

Reference:

1. Wegovy. Semaglutide Tablets 25 mg || Semaglutide Injection 1.7 mg/ 2.4 mg / 7.2 mg. Prescribing Information. Last Revised: March 2026. Accessed on: 14th April 2026.  Click Here

2. GLP-1 Drugs Use, Risks, and Regulation. Last Revised: 1st April 2026. Accessed on: 14th April 2026. >Click Here

3. Obesity: GLP-1 therapies. World Health Organization. Accessed on: 14th April 2026. Click Here

4. CDSCO. SL. No. 3 & 4. Accessed on: 14th April 2026. Click Here